Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs An explorative study.
The aim of this study was to explore the pharmacokinetics of the two main active compounds (THC and CBD) contained in the cannabis oil extract Bedrocan® in fasting and fed dogs. Bedrocan® (20% delta-9-tetrahydrocannabinol THC and 0.5% cannabidiol CBD) was administered at 1.5 and 0.037 mgkg THC and CBD, respectively in fasted and fed dogs according to a 2 × 2 cross over study design. The quantification of the two active ingredients was performed by LCMS. No detectable concentrations of CDB were found at any collection time. THC was quantifiable from 0.5 to 10 h, although there was large inter-subject variability. Fed dogs showed a longer absorption phase (Tmax 5 vs 1.25 h) and lower maximal blood concentration (7.1 vs 24 ngmL) compared with the fasted group. A larger AUC was found in the fasted group the relative oral bioavailability in fed animals was 48.22%.